Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology with human disease to advance novel therapeutics that target and improve the integrity of the intestinal barrier.
Company profile
Ticker
PALI
Exchange
Website
CEO
Kenneth Carter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Seneca Biopharma, Inc., Neuralstem, Inc.
SEC CIK
Corporate docs
Subsidiaries
Leading Biosciences, Inc. • Suzhou Neuralstem Biopharmaceutical Co., Ltd. ...
IRS number
522007292
PALI stock data
Latest filings (excl ownership)
8-K
Other Events
10 Apr 24
EFFECT
Notice of effectiveness
8 Apr 24
424B3
Prospectus supplement
5 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
5 Apr 24
S-3
Shelf registration
29 Mar 24
S-8
Registration of securities for employees
29 Mar 24
8-K
Results of Operations and Financial Condition
27 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Departure of Directors or Certain Officers
6 Mar 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
Latest ownership filings
4
John David Finley
12 Mar 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
James R Neal
13 Feb 24
4
Cristina Csimma
13 Feb 24
4
Robert J. Trenschel
13 Feb 24
4
Stephanie Diaz
13 Feb 24
SC 13G/A
L1 Capital Global Opportunities Master Fund, Ltd.
9 Feb 24
4
Mitchell Lawrence Jones
8 Feb 24
4
John David Finley
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.34 mm | 15.34 mm | 15.34 mm | 15.34 mm | 15.34 mm | 15.34 mm |
Cash burn (monthly) | 363.67 k | (no burn) | 1.26 mm | 1.15 mm | 887.33 k | 974.42 k |
Cash used (since last report) | 2.42 mm | n/a | 8.38 mm | 7.63 mm | 5.90 mm | 6.48 mm |
Cash remaining | 12.92 mm | n/a | 6.96 mm | 7.71 mm | 9.43 mm | 8.85 mm |
Runway (months of cash) | 35.5 | n/a | 5.5 | 6.7 | 10.6 | 9.1 |
Institutional ownership, Q2 2023
19.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 231.70 mm |
Total shares | 2.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Regional Medical Center Yuma | 2.25 mm | $5.55 mm |
Intracoastal Capital | 131.09 k | $0.00 |
Geode Capital Management | 42.25 k | $71.82 mm |
Vanguard | 35.57 k | $60.47 mm |
Lind Global Fund II | 30.99 k | $0.00 |
BAC Bank Of America | 30.00 k | $51.00 mm |
STT State Street | 22.46 k | $38.19 mm |
MS Morgan Stanley | 2.04 k | $3.47 mm |
WFC Wells Fargo & Co. | 372.00 | $633.00 k |
Advisor | 221.00 | $376.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | John David Finley | Common Stock, par value $0.01 | Option exercise | Acquire M | No | No | 0 | 5,558 | 0.00 | 96,849 |
11 Mar 24 | John David Finley | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,558 | 0.00 | 50,025 |
9 Feb 24 | Neal James R | Common Stock, par value $0.01 | Option exercise | Acquire M | No | No | 0 | 5,820 | 0.00 | 10,920 |
9 Feb 24 | Neal James R | Common Stock, par value $0.01 | Option exercise | Acquire M | No | No | 0 | 5,100 | 0.00 | 5,100 |
9 Feb 24 | Neal James R | Common Stock | Option exercise | Acquire M | No | No | 0.59 | 6,880 | 4.06 k | 6,880 |
9 Feb 24 | Neal James R | Common Stock | Option exercise | Dispose M | No | No | 0.59 | 6,880 | 4.06 k | 0 |
9 Feb 24 | Neal James R | Common Stock | Option exercise | Acquire M | No | No | 1.6 | 12,160 | 19.46 k | 12,160 |
9 Feb 24 | Neal James R | Common Stock | Option exercise | Dispose M | No | No | 1.6 | 12,160 | 19.46 k | 0 |
9 Feb 24 | Neal James R | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,820 | 0.00 | 0 |
9 Feb 24 | Neal James R | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,100 | 0.00 | 0 |
News
Looking Into Palisade Bio's Recent Short Interest
17 Apr 24
S&P 500 Edges Lower; PacBio Shares Plunge
16 Apr 24
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
Maxim Group Maintains Buy on Palisade Bio, Adjusts Price Target To $22.5 (reverse stock split 1:15)
16 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
16 Apr 24
Press releases
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool
16 Apr 24
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
11 Apr 24
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™
10 Apr 24
Palisade Bio Announces 1-for-15 Reverse Stock Split
3 Apr 24
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
27 Mar 24